# Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease

> **NCT02833792** · PHASE2 · UNKNOWN · sponsor: **Stemedica Cell Technologies, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Alzheimer Dementia

## Interventions

- **DRUG:** Human Mesenchymal Stem Cells and Lactated Riunger's Solution
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02833792
- **Lead sponsor:** Stemedica Cell Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06-01
- **Primary completion:** 2024-07-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02833792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02833792, "Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02833792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*